推荐产品
生物源
mouse
品質等級
抗體表格
purified antibody
抗體產品種類
primary antibodies
無性繁殖
MS110, monoclonal
形狀
liquid
包含
≤0.1% sodium azide as preservative
物種活性
human
製造商／商標名
Calbiochem®
儲存條件
do not freeze
同型
IgG1
運輸包裝
wet ice
儲存溫度
2-8°C
目標翻譯後修改
unmodified
基因資訊
human ... BRCA1(672)
一般說明
可识别MCF-7细胞中的~220 kDa BRCA1蛋白。不与血型抗原或生长因子受体（如EGFR）发生交叉反应。根据美国专利号5,753,441和6,162,897的许可证销售。
抗BRCA1（Ab-1），小鼠单克隆，克隆MS110，可识别MCF-7细胞中的~220 kDa BRCA1蛋白。它经过验证可用于冷冻和石蜡切片的WB、IF、IP分析。
通过用指定的免疫原免疫小鼠并将脾细胞与NS1小鼠骨髓瘤细胞融合而产生的纯化小鼠单克隆抗体。可识别~220 kDa BRCA1蛋白。
免疫原
人
表位：BRCA1的N末端304个氨基酸内
重组人BRCA1
應用
冰冻切片（见应用参考文献）
免疫印迹（2 µg/ml）
免疫荧光（见应用参考文献）
免疫沉淀（见应用参考文献）
石蜡切片（见应用参考文献）
免疫印迹（2 µg/ml）
免疫荧光（见应用参考文献）
免疫沉淀（见应用参考文献）
石蜡切片（见应用参考文献）
包裝
请参考特定浓度批号的标签。
警告
毒性：标准处理（A）
外觀
溶于50 mM磷酸钠缓冲液（pH 7.5），含0.2％明胶。
分析報告
阳性对照
MCF7细胞
MCF7细胞
其他說明
Scully, R., et al. 1996.Science272, 123.
Gudas, J.M., et al. 1996.Cell Growth Differ.7, 717.
Vaughn, J.P., et al. 1996.Cell Growth Differ.7, 711.
Goldgar, D.E. and Reilly, P.R.1995.Nat. Genet.11, 113.
Merajver, S.D., et al. 1995.Clin. Can.Res.1, 539.
Merajver, S.D., et al. 1995.Nat. Genet.9, 439.
Struewing, J.P., et al. 1995.Nat. Genet.11, 198.
Thompson, M.E., et al. 1995.Nat. Genet.9, 444.
Futreal, P.A., et al. 1994.Science266, 120.
Miki, Y., et al. 1994.Science266, 66.
Wilson, C.A., et al. 1999.Nat. Genet.21, 236.
Gudas, J.M., et al. 1996.Cell Growth Differ.7, 717.
Vaughn, J.P., et al. 1996.Cell Growth Differ.7, 711.
Goldgar, D.E. and Reilly, P.R.1995.Nat. Genet.11, 113.
Merajver, S.D., et al. 1995.Clin. Can.Res.1, 539.
Merajver, S.D., et al. 1995.Nat. Genet.9, 439.
Struewing, J.P., et al. 1995.Nat. Genet.11, 198.
Thompson, M.E., et al. 1995.Nat. Genet.9, 444.
Futreal, P.A., et al. 1994.Science266, 120.
Miki, Y., et al. 1994.Science266, 66.
Wilson, C.A., et al. 1999.Nat. Genet.21, 236.
在单个系统中，应对抗体进行滴定以获得最佳结果。
法律資訊
根据美国专利号5,753,441和6,162,897的许可证销售。
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
儲存類別代碼
10 - Combustible liquids
水污染物質分類（WGK）
nwg
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Nerea Matamala et al.
Oncotarget, 7(15), 20068-20079 (2016-03-05)
Emerging evidence suggests that BRCA1 pathway contributes to the behavior of sporadic triple negative breast cancer (TNBC), but little is known about the mechanisms underlying this association. Considering the central role that microRNAs (miRNAs) play in gene expression regulation, the
Aruna Korlimarla et al.
PloS one, 11(4), e0153113-e0153113 (2016-04-15)
Apart from germ-line BRCA1-mutated breast cancers, a significant proportion of women with sporadic triple negative breast cancer (TNBC) sub-type are known to harbour varying levels of BRCA1-dysfuction. There is currently no established diagnostic method to identify these patients. The analysis
Geon Kim et al.
Oncology letters, 17(6), 5023-5029 (2019-06-13)
Breast cancer type 1 susceptibility protein (BRCA1) is a tumor suppressor gene that encodes a nuclear phosphoprotein, which is involved in homologous recombination to repair DNA double strand breaks and maintain genome stability. When BRCA1 is mutated or altered, DNA
Pierre Thouvenot et al.
Journal of cell science, 129(23), 4366-4378 (2016-11-02)
Understanding the effect of an ever-growing number of human variants detected by genome sequencing is a medical challenge. The yeast Saccharomyces cerevisiae model has held attention for its capacity to monitor the functional impact of missense mutations found in human
Young Eun Choi et al.
Oncotarget, 5(9), 2678-2687 (2014-05-07)
The promise of PARP-inhibitors(PARPis) in the management of epithelial ovarian cancer(EOC) is tempered by the fact that approximately 50% of patients with homologous recombination (HR)-proficient tumors do not respond well to these agents. Combination of PARPis with agents that inhibit
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门